Ferrari R
Cattedra di Cardiologia, Università degli Studi, Brescia.
Cardiologia. 1994 Dec;39(12 Suppl 1):203-6.
We have considered the possibility that the association between Ca(2+)-antagonists and ACE-inhibitors may be useful to treat patients with myocardial infarction. The two classes of drugs have synergic and complementary effects in terms of mechanism and site of action and of cardioprotective properties. In clinical trials Ca(2+)-antagonists failed to improve prognosis of patients with myocardial infarction, except verapamil which reduces mortality in patients with myocardial infarction and without pulmonary congestion. ACE-inhibitors are effective only in patients with myocardial infarction and congestive heart failure. Thus the two classes of drugs could be useful to treat patients with myocardial infarction but this hypothesis has to be confirmed with properly designed clinical trials.
我们已经考虑过钙拮抗剂与血管紧张素转换酶抑制剂联合使用可能有助于治疗心肌梗死患者的可能性。这两类药物在作用机制、作用部位和心脏保护特性方面具有协同和互补作用。在临床试验中，除维拉帕米可降低无肺淤血的心肌梗死患者的死亡率外，钙拮抗剂未能改善心肌梗死患者的预后。血管紧张素转换酶抑制剂仅对心肌梗死合并充血性心力衰竭的患者有效。因此，这两类药物可能对治疗心肌梗死患者有用，但这一假设必须通过精心设计的临床试验来证实。
